Prostate

Active Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)

Volunteers
Health Professionals

What is the purpose of this trial?

The objective in this study is to determine if MRI-identified progression can decrease frequency or need for repeated prostate biopsy in men on active surveillance (AS).

Our hypothesis is that MRI alone is adequate to detect progression of prostate cancer in men on active surveillance (AS) after a MRI-US fusion prostate biopsy.

Trial with
Yale Cancer Center
Ages
30 years - 80 years
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Elizabeth Szymanski

beth.szymanski@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Preston C. Sprenkle, MD
Associate Professor of Urology; Co-Chair, Cancer Liaison Committee, Oncology; Co-Chair, NCCN Guidelines Committee on Prostate Cancer Early Detection; Division Chief, Division of Urology at VA Connecticut Healthcare System, Urology; Director, Urology Research Fellowship, Urology; Director, Urologic Oncology Clinical Fellowship Program, Urology

Sub-Investigators

Last Updated
10/03/2023
Study HIC
#1501015246